Status:
COMPLETED
Predicting Reduction of Hypertension After Adrenalectomy for Primary Aldosteronism: a Multicenter Analysis
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
University of California, San Francisco
Northwestern Memorial Hospital
Conditions:
Primary Aldosteronism Due to Aldosterone Producing Adenoma
Primary Aldosteronism
Eligibility:
All Genders
18+ years
Brief Summary
Primary aldosteronism (PA) is the excessive endogenous production of the mineralocorticoid aldosterone. Although various rare forms of PA exist, the vast majority of cases are accounted by either an a...
Eligibility Criteria
Inclusion
- All patients who underwent unilateral adrenalectomy between 2010 and 2016 for APA.
- Patients with biochemical evidence of primary aldosteronism who underwent adrenalectomy on account of an aldosterone-producing adenoma(APA), proven by Computerized Tomography(CT) or Magnetic Resonance Imaging(MRI) or Adrenal Venous Sampling(AVS).
Exclusion
- Age \<18 years.
- Missing or incomplete data about preoperative blood pressure and number of antihypertensive drugs.
- Missing or incomplete follow-up data about postoperative blood pressure and number of antihypertensive drugs. We aim enter the blood pressure and number of antihypertensive drugs closest to 6 months after adrenalectomy.
Key Trial Info
Start Date :
March 26 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 26 2017
Estimated Enrollment :
514 Patients enrolled
Trial Details
Trial ID
NCT04761354
Start Date
March 26 2016
End Date
March 26 2017
Last Update
February 18 2021
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Francisco
San Francisco, California, United States, 94143
2
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
3
University of Chicago Medical Center
Chicago, Illinois, United States, 60637
4
Boston Medical Center
Boston, Massachusetts, United States, 02118